COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Clinical Effectiveness Of High Frequency Chest Wall Oscillation (HFCWO) In A Bronchiectasis Population (HFCWO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04271969
Recruitment Status : Recruiting
First Posted : February 17, 2020
Last Update Posted : March 5, 2020
University of Alabama at Birmingham
Information provided by (Responsible Party):
Electromed, Inc.

Brief Summary:
The primary objective is to compare the patient's baseline QoL prior to HFCWO use against the patient's QoL at various study timepoints over a one-year period of HFCWO use.

Condition or disease Intervention/treatment
Bronchiectasis Device: SmartVest Airway Clearance System

Detailed Description:
This study will use a prospective interventional comparative study design using the patient's quality of life (QoL) as the primary study endpoint to determine HFCWO affect. The study will compare the patient's QoL baseline (established at enrollment prior to HFCWO treatment) to the QoL measured at various timepoints (enrollment, 2 months, 6 months and 12 months) over a one-year period whilst receiving HFCWO treatment. In addition, a baseline for the secondary endpoints will established at enrollment for comparison to measurements taken at various timepoints over a one-year period whilst receiving HFCWO treatment. The patient's medical records will be used to establish prior histories of exacerbation rates for comparison to exacerbation rates experienced after one year of HFCWO treatment. Patients will serve as their own control.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Clinical Effectiveness Of High Frequency Chest Wall Oscillation (HFCWO) In A Bronchiectasis Population
Estimated Study Start Date : February 29, 2020
Estimated Primary Completion Date : June 2021
Estimated Study Completion Date : June 2021

Intervention Details:
  • Device: SmartVest Airway Clearance System
    Pulmonary airway clearance of retained mucus via high frequency chest wall oscillation (SmartVest)

Primary Outcome Measures :
  1. Quality of Life (QoL): Quality of Life-Bronchiectasis (QOL-B) questionnaire [ Time Frame: 1 year ]

    The primary endpoint is the subject's quality of life (QoL) using the Quality of Life-Bronchiectasis (QOL-B) questionnaire as the measurement tool. QoL measured at enrollment (baseline) will be compared to QoL measured at 2 months, 6 months and 1 year.

    The previously validated questionnaire is titled "Quality of Life Questionnaire - Bronchiectasis". The Likert style questionnaire asks the subject to subjectively rank their symptoms using a 4 scale base ranging from "a lot of difficulty" to "no difficulty" and "always" to "never".

Secondary Outcome Measures :
  1. Clinical Measurements [ Time Frame: 1 year ]
    1. Exacerbation rates

      a. Pre HFCWO exacerbation rates will be established by review of the patient's medical records. Post HFCWO will recorded at 2 months, 6 months and 1 year.

    2. Exacerbation frequency

      1. The time to the subject's next exacerbation will be recorded for comparison pre to post HFCWO
      2. Lung function (FEV1, FVC, FEF25-75) measured by standard spirometry
      3. Sputum production measured by using the Breathlessness, Cough and Sputum Scale (BCSS) questionnaire
      4. Patient adherence to HFCWO treatment measured by SmartVest Connect wireless feature
      5. Six-minute walk test measured using American Thoracic Society standard test guidelines/protocol
      6. Radiographic changes compare patient's original high-resolution computerized tomography (HRCT) taken to initially

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Primary care clinic

Inclusion Criteria:

  1. 18 years of age or older
  2. Previous diagnosis of bronchiectasis confirmed by HRCT within the last 6 months
  3. Patients must have at least 6 months of medical records related to bronchiectasis
  4. Patients must be stable and currently on a standard of care regimen for bronchiectasis such as hypertonic saline and/or PEP
  5. Patients with 1 or more exacerbations within the last 12 months
  6. Previous and existing productive cough
  7. No previous HFCWO use

Exclusion Criteria:

  1. Patients who are known to have cystic fibrosis
  2. Patients who are known to have primary ciliary dyskinesia (PCD)
  3. Patients with chronic obstructive pulmonary disease (COPD) without bronchiectasis
  4. Patients breathing via an artificial airway
  5. Severe bronchospasm based on exam or history
  6. Any comorbidity(ies) or contraindications that would normally complicate tolerating HFCWO treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04271969

Layout table for location contacts
Contact: Chet Sievert 651-246-8621

Layout table for location information
United States, Alabama
University of Alabama - Birmingham (UAB University Hospital) Recruiting
Birmingham, Alabama, United States, 35233-2110
Contact: George Solomon, MD    205-996-4975   
Contact: Heather Hathorne, PhD    205-638-9568   
United States, Georgia
Emory University School of Medicine Not yet recruiting
Atlanta, Georgia, United States, 30342
Contact: Colin Swenson, MD   
United States, Ohio
Cleveland Clinic Not yet recruiting
Cleveland, Ohio, United States, 44195
Contact: Elliot Dasenbrook, MD   
Contact: David Weaver    216-445-6671    weaverd@ccf.rg   
United States, Texas
The University of Texas Health Science Center at Tyler Recruiting
Tyler, Texas, United States, 75708
Contact: Julie Philley, MD    903-877-5803   
Contact: Pernelia Grundy    903-877-7505   
Sponsors and Collaborators
Electromed, Inc.
University of Alabama at Birmingham
Layout table for investigator information
Principal Investigator: George Solomon, MD University of Alabama at Birmingham
Layout table for additonal information
Responsible Party: Electromed, Inc. Identifier: NCT04271969    
Other Study ID Numbers: HFCWO-001
First Posted: February 17, 2020    Key Record Dates
Last Update Posted: March 5, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Electromed, Inc.:
Additional relevant MeSH terms:
Layout table for MeSH terms
Bronchial Diseases
Respiratory Tract Diseases